Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Falk Steffen

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Journal of Neuroinflammation|November 14, 2023
Spatial transcriptomics and neurofilament light chain reveal changes in lesion patterns in murine autoimmune neuroinflammationTobias Brummer, Miriam Schillner, Falk Steffen, et al.
Therapeutic Advances in Neurological Disorders|December 26, 2022
Comparative effectiveness of natalizumab <i>versus</i> ocrelizumab in multiple sclerosis: a real-world propensity score-matched studyKatrin Pape, Leoni Rolfes, Falk Steffen, et al.
Journal of Neurology|December 19, 2025
Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimensAgni M Konitsioti, Finja Schweitzer, Wibke Johannis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2019
Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MSSinah Engel, Michaela Friedrich, Muthuraman Muthuraman, et al.
Therapeutic Advances in Neurological Disorders|May 7, 2021
Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosisSinah Engel, Maria Protopapa, Falk Steffen, et al.
Frontiers in Neurology|March 28, 2019
Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive NeurodegenerationKatharina Birkner, Julia Loos, René Gollan, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 31, 2022
Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple SclerosisYavor Yalachkov, Jan Hendrik Schäfer, Jasmin Jakob, et al.
Therapeutic Advances in Neurological Disorders|November 24, 2025
Prognostic value of blood-based biomarkers in multiple sclerosis patients in the absence of clinical relapses or new MRI lesionsTobias Brummer, Gabriel Gonzalez-Escamilla, Falk Steffen, et al.
European Journal of Neurology|May 23, 2025
Glial Fibrillary Acid Protein Reflects Disease Activity in Autoimmune EncephalitisJohannes Piepgras, Marlene L Piepgras, Falk Steffen, et al.
Brain Communications|July 11, 2022
Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkersTobias Brummer, Muthuraman Muthuraman, Falk Steffen, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Journal of Neuroinflammation|November 14, 2023
Spatial transcriptomics and neurofilament light chain reveal changes in lesion patterns in murine autoimmune neuroinflammationTobias Brummer, Miriam Schillner, Falk Steffen, et al.
Therapeutic Advances in Neurological Disorders|December 26, 2022
Comparative effectiveness of natalizumab <i>versus</i> ocrelizumab in multiple sclerosis: a real-world propensity score-matched studyKatrin Pape, Leoni Rolfes, Falk Steffen, et al.
Journal of Neurology|December 19, 2025
Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimensAgni M Konitsioti, Finja Schweitzer, Wibke Johannis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 28, 2019
Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MSSinah Engel, Michaela Friedrich, Muthuraman Muthuraman, et al.
Therapeutic Advances in Neurological Disorders|May 7, 2021
Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosisSinah Engel, Maria Protopapa, Falk Steffen, et al.
Frontiers in Neurology|March 28, 2019
Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive NeurodegenerationKatharina Birkner, Julia Loos, René Gollan, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 31, 2022
Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple SclerosisYavor Yalachkov, Jan Hendrik Schäfer, Jasmin Jakob, et al.
Therapeutic Advances in Neurological Disorders|November 24, 2025
Prognostic value of blood-based biomarkers in multiple sclerosis patients in the absence of clinical relapses or new MRI lesionsTobias Brummer, Gabriel Gonzalez-Escamilla, Falk Steffen, et al.
European Journal of Neurology|May 23, 2025
Glial Fibrillary Acid Protein Reflects Disease Activity in Autoimmune EncephalitisJohannes Piepgras, Marlene L Piepgras, Falk Steffen, et al.
Brain Communications|July 11, 2022
Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkersTobias Brummer, Muthuraman Muthuraman, Falk Steffen, et al.
Pageof 6